Elanco Announces Collaboration Agreement with Novozymes for Nutritional Health Innovation
November 02 2018 - 6:45AM
Business Wire
The collaboration furthers Elanco’s commitment
to antibiotic stewardship and offering alternatives to unmet
needs.
Elanco Animal Health Incorporated (NYSE:ELAN), announced today a
new global R&D collaboration with Novozymes A/S (OMX: NZYM B),
the world leader in biological solutions, to develop nutritional
health products for beef cattle and dairy cows globally.
The effort will leverage Novozymes’ leading discovery and
development programs, and together the companies will collaborate
to develop a R&D pipeline and commercialize products in the
next decade.
“Nutritional health is an exciting platform that will define the
next generation of feed additives to improve the health and
performance of food animals,” said Aaron Schacht, executive vice
president, Innovation, Regulatory and Business Development of
Elanco Animal Health. “This collaboration expands our growing
nutritional health capability into cattle and underscores Elanco’s
commitment to bring producers innovative alternatives to
antibiotics, while preserving the health and welfare of the
animal.”
Identifying and developing new products and tools to help manage
the animal’s microbiome, control infections, and reduce gut
inflammation while decreasing the need for medically important
antibiotics is a top priority for Elanco.
“We are excited to collaborate with Elanco to develop
nutritional health products for dairy cows and beef cattle
production that can improve sustainability in the industry,” said
Susanne Palsten Buchardt, vice president, Animal Health &
Nutrition at Novozymes. “The collaboration is an important step in
our efforts to deliver sustainable solutions for better lives in a
growing world.”
Applying new biological and sustainable tools for animal health
and nutrition in cattle production is more challenging with their
complicated digestive systems, longer lives and less integrated
production with significantly more co-mingling of animals.
Partnering the complementary capabilities of Elanco and Novozymes,
from research to commercialization, will further advance these
efforts.
“The world leading research, development and production
capabilities from Novozymes, combined with Elanco’s global
commercial presence, is a great match and together we will bring
innovative solutions to meet diverse customer and consumer needs,”
Schacht said.
As part of Elanco’s 8-point Antibiotic Stewardship Plan released
in 2015, Elanco aims to deliver a total of 25 viable antibiotic
alternative development projects by 2020 that address critical
unmet challenges in livestock production and reduce the need for
shared‐class antibiotics that are also critical to human medicine.
To date, Elanco has identified and added 16 alternative development
projects to its pipeline.
About Elanco
Founded in 1954, Elanco provides comprehensive products and
knowledge services to improve animal health and food-animal
production in more than 90 countries around the world. We value
innovation, both in scientific research and daily operations, and
strive to cultivate a collaborative work environment for more than
5,800 employees worldwide. Together with our customers, we are
committed to raising awareness about global food security, and
celebrating and supporting the human-animal bond. Our worldwide
headquarters and research facilities are located in Greenfield,
Indiana.
About Novozymes
Novozymes is the world leader in biological solutions. Together
with customers, partners and the global community, we improve
industrial performance while preserving the planet’s resources and
helping build better lives. As the world’s largest provider of
enzyme and microbial technologies, our bioinnovation enables higher
agricultural yields, low-temperature washing, energy-efficient
production, renewable fuel and many other benefits that we rely on
today and in the future.We call it Rethink Tomorrow.
www.novozymes.com
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about a collaboration agreement between Elanco and Novozymes,
and reflects Elanco’s current belief. However, as with any
collaboration, there are substantial risks and uncertainties in the
process of development and commercialization. Among other things,
there can be no guarantee that this collaboration will be
commercially successful. For further discussion of these and other
risks and uncertainties, see Elanco’s most recent filings with the
United States Securities and Exchange Commission. Except as
required by law, Elanco undertakes no duty to update
forward-looking statements to reflect events after the date of this
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181102005088/en/
Elanco Animal HealthColleen Parr Dekker,
317-989-7011colleen_parr_dekker@elanco.com
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Jul 2023 to Jul 2024